Q3 2022

Filed Nov 14, 2022 · 10-Q · 45 days after period end · 0001640334-22-002451

Q3 2022 · 10-Q

Revenue

$3.34K

−37.5% vs Q3 2021

Net Income

-$276.33K

N/M vs Q3 2021

EPS, diluted—

Gross Profit$2,000−35.8%

Operating Cash Flowderived-$66,608N/M

Same quarter

Metric	Q3 2022	Q3 2021	Q3 2020	Q3 2019
Revenue	$3.34K	$5.34K	$4.44K	$2.08K
Net Income	-$276.33K	-$34.52K	-$13.46K	-$54.91K
EPS Diluted	—	$0.00	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bioadaptives, Inc. · CIK 1575142 · Engraved from SEC EDGAR